The Effects of Exenatide Microsphere on Serum BGP and ALP Levels in ZDF Rats after Implantation.
Clin Implant Dent Relat Res · 2015
Last updated 2026-05-28In a study on diabetic rats with dental implants, those treated with insulin (groups B and C) showed different levels of bone markers compared to untreated diabetic rats (group A). After 14 days, bone Gla protein (BGP) levels were significantly higher in rats with steady blood sugar control (group C), while alkaline phosphatase (ALP) levels were significantly higher in both insulin-treated groups at 30 days.
AI summary of the abstract below.
| Journal | Clin Implant Dent Relat Res, 2015 |
|---|---|
| Citations | 12 |
| Relative citation ratio | 0.64 |
| NIH percentile | 36 |
| Molecules | exenatide |
| Conditions studied | Type 2 Diabetes |
Abstract
PURPOSE: The aim of this project is to investigate the impact of diabetes mellitus and different glycemic control times on early osseointegration of dental implants by expression and significance of serum bone Gla protein (BGP) and alkaline phosphatase (ALP) levels in Zucker diabetic fatty (ZDF) rats after implantation.
MATERIALS AND METHODS: The animals were divided into three groups, each group with 11 rats and each rat with two dental implants (33 rats and 66 implants in total): group A, diabetic rats with dental implants (controls); group B, diabetic rats treated with insulin and implants placed simultaneously; and group C, diabetic rats treated with insulin until serum glucose at a constant level and then implants be placed. Levels of BGP and ALP in the serum were measured by enzyme-linked immunosorbent assay in each group. The software program SPSS (version 17.0 for Windows) was used to analyze all data; p < .05 was set as the level of statistical significance.
RESULTS: At the 7th day, serum levels of BGP in group B and C were lower than that in group A (p > 0.05). At the 14th day, serum levels of BGP in group C were significantly higher (p < 0.05). After 30 days, compared with group A, the serum levels of BGP in group B and C seems to be lower. Compared with group A, the serum levels of ALP in group B and C were significantly higher, whereas the serum levels of ALP in group C seems to be higher than B (p < 0.05).
CONCLUSIONS: The present results suggest that injection of delayed release microsphere of exenatide on ZDF rats can release exenatide at a steady rate and the blood glucose can be controlled at a constant level. Implant survival rates could be enhanced in DM subjects when blood plasma glucose level is under control; the serum levels of BGP in this study seems to have no relationship with local osseointegration, whereas the serum levels of ALP might offer insights into the activity of osseointegration around the implant surface.
Verbatim abstract via PubMed 24299614 ↗
Related research
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Exenatide and the treatment of patients with Parkinson's disease.
- Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.